Peripheral T-Cell Lymphoma, Not Otherwise Specified

Peripheral T-Cell Lymphoma, Not Otherwise Specified — Trials · CancerIndex

Clinical trials

Registered studies

299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 72
Recruiting: 44
Ph III recruiting: 7
Growth YoY: —
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 29.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (41)

clinicaltrialsPublishedShowing 1–50 of 66 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02223208	Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas(FIL_PTCL13)	completed	Phase 1 / Phase 2	89	Fondazione Italiana Linfomi - ETSOTHER	1	Aug 19, 2026	clinicaltrials
NCT04569032	A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression	completed	Phase 2	82	Seagen, a wholly owned subsidiary of PfizerINDUSTRY	5